alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 37 studies in Hippocampus size on brain scans of type cross-sectional study (page 1 of 2) · 30,980 in the whole library · How the 0–100 score works

Download bibliography of these 37 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

What “Hippocampus size on brain scans” covers

Hippocampus size on brain scans — Studies that measure the hippocampus, a part of the brain central to memory, usually on MRI, and what its shrinking says about memory loss.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2021-04-01

Patients with preserved cognition and mild-verbal memory/semantic fluency were younger (mean [SD] age, 36.5 [9.8] years and 38.2 [11.1] years) and had shorter disease duration (mean [SD] 8.0 [7.3] years and 8.3 [7.6] years) compared with patients with mild-multidomain (mean [SD] age, 42.6 [11.2] years; mean [SD] disease duration, 12.8 [9.6] years; P < .001), severe-executive/attention (mean [SD] age, 42.9 [11.7] years; mean [SD] disease duration, 12.2 [9.5] years; P < .001), and severe-multidomain (mean [SD] age, 44.0 [11.0] years; mean [SD] disease duration, 13.3 [10.2] years; P < .001) phenotypes. 3 key findings →

Design: cross-sectional Participants: 235 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middle-aged adults: the Framingham Offspring Study

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Diabetes care 2011-06-16

Metabolic dysregulation, especially insulin resistance, was associated with lower brain volumes and executive function in a large, relatively healthy, middle-aged, community-based cohort. 3 key findings →

Design: cross-sectional Participants: 2,439 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Higher glucose levels associated with lower memory and reduced hippocampal microstructure

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Neurology 2013-10-23

Our results indicate that even in the absence of manifest type 2 diabetes mellitus or impaired glucose tolerance, chronically higher blood glucose levels exert a negative influence on cognition, possibly mediated by structural changes in learning-relevant brain areas. 4 key findings →

Design: cross-sectional Participants: 141 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Neurology 1998-10-01

A statistically significant yearly decline in hippocampal volume and an increase in temporal horn volume was identified in elderly control subjects who represent typical aging individuals. 4 key findings →

Design: cross-sectional Participants: 24 Evidence: low

Full summary, score breakdown and related studies → Original source

A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Journal of psychiatry & neuroscience : JPN 2009-01-01

Although all studies were cross-sectional, our results suggest that hippocampal volume reductions generally occur after disease onset in patients with MDD. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source

Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people

✓ Peer-reviewed alzhub usefulness score 57 out of 100. JAMA neurology 2013-12-01

Such findings challenge the proposed sequence and suggest that Aβ-independent precursors underlie AD-typical neurodegenerative patterns. 3 key findings →

Design: cross-sectional Participants: 29 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Archives of neurology 2009-12-01

The in vivo measure of cerebral amyloidosis known as [(11)C]PiB is associated with cross-sectional regionally specific brain atrophy and longitudinal cognitive decline in multiple cognitive domains that occur before the clinical diagnosis of Alzheimer disease. 4 key findings →

Design: cross-sectional Participants: 135 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Archives of general psychiatry 2006-02-01

Patients with chronic schizophrenia displayed bilateral hippocampal volume reduction. 4 key findings →

Design: cross-sectional Participants: 89 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Hippocampal volumetric and morphometric studies in frontal and temporal lobe epilepsy

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Brain : a journal of neurology 1992-08-01

The most common temporal lobe pathology is Ammons Horn sclerosis (AHS), and several different imaging techniques have been utilized to detect this with varying success. 3 key findings →

Design: cross-sectional Participants: 20 Evidence: low

Full summary, score breakdown and related studies → Original source

Structural Plasticity of the Hippocampus and Amygdala Induced by Electroconvulsive Therapy in Major Depression

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Biological psychiatry 2015-03-05

ECT-induced neuroplasticity in the hippocampus and amygdala relates to improved clinical response and is pronounced in regions with prominent connections to ventromedial prefrontal cortex and other limbic structures. 2 key findings →

Design: cross-sectional Participants: 43 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Structural changes in the hippocampus in major depressive disorder: contributions of disease and treatment

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of psychiatry & neuroscience : JPN 2010-09-01

Our results suggest that decreased hippocampal tail and hippocampal head volumes could be trait changes, whereas hippocampal body changes may be dependent on treatment. 5 key findings →

Design: cross-sectional Participants: 39 Evidence: low

Full summary, score breakdown and related studies → Original source

Amygdala, hippocampal and corpus callosum size following severe early institutional deprivation: the English and Romanian Adoptees study pilot

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of child psychology and psychiatry, and allied disciplines 2009-04-17

The adoption into the UK of children who have been reared in severely deprived conditions provides an opportunity to study possible association between very early negative experiences and subsequent brain development. 1 key finding →

Design: cross-sectional Participants: 14 Evidence: low

Full summary, score breakdown and related studies → Original source

Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Brain : a journal of neurology 2015-09-30

We recently demonstrated that the frequencies of biomarker groups defined by the presence or absence of both amyloidosis (A+) and neurodegeneration (N+) changed dramatically by age in cognitively non-impaired subjects. 4 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source

Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neuroscience 2015-12-30

Neuroimaging and postmortem studies of subjects with major depressive disorder (MDD) reveal smaller hippocampal volume with lengthening duration of illness. 4 key findings →

Design: cross-sectional Participants: 17 Evidence: low

Full summary, score breakdown and related studies → Original source

The neurodevelopmental impact of childhood onset temporal lobe epilepsy on brain structure and function and the risk of progressive cognitive effects

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Progress in brain research 2002-01-01

The purpose of this study is to explore the possibility of progressive neuropsychological decline in chronic temporal lobe epilepsy (TLE) and determine how this vulnerability may be associated with the neurodevelopmental impact of the disorder. 53 patients with TLE and 62 healthy controls underwent quantitative MRI volumetric imaging of total brain tissue and hippocampal volumes as well as assessment of intelligence and memory function. 5 key findings →

Design: cross-sectional Participants: 53 Evidence: low

Full summary, score breakdown and related studies → Original source

Childhood socioeconomic status and adult brain size: childhood socioeconomic status influences adult hippocampal size

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Annals of neurology 2012-05-01

A significant association between childhood SES and hippocampal volumes in late life is consistent with the established neurodevelopmental findings that early life conditions have an effect on structural brain development. 2 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events